This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Oxurion Past Earnings Performance
Past criteria checks 0/6
Key information
-2.4%
Earnings growth rate
-1.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -29.8% |
| Return on equity | n/a |
| Net Margin | -2,584.9% |
| Next Earnings Update | 24 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Oxurion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 1 | -29 | 8 | 21 |
| 30 Sep 21 | 1 | -30 | 9 | 22 |
| 30 Jun 21 | 1 | -31 | 9 | 23 |
| 31 Mar 21 | 2 | -29 | 9 | 23 |
| 31 Dec 20 | 2 | -28 | 9 | 22 |
| 30 Sep 20 | 3 | -30 | 10 | 23 |
| 30 Jun 20 | 3 | -32 | 11 | 24 |
| 31 Mar 20 | 4 | -42 | 12 | 25 |
| 31 Dec 19 | 4 | -52 | 13 | 26 |
| 30 Sep 19 | 4 | -54 | 14 | 27 |
| 30 Jun 19 | 3 | -57 | 14 | 28 |
| 31 Mar 19 | 4 | -48 | 13 | 29 |
| 31 Dec 18 | 5 | -38 | 13 | 30 |
| 30 Sep 18 | 6 | -8 | 12 | 28 |
| 30 Jun 18 | 7 | 23 | 11 | 26 |
| 31 Mar 18 | 6 | 23 | 11 | 25 |
| 31 Dec 17 | 6 | 23 | 10 | 23 |
| 30 Sep 17 | 6 | -19 | 10 | 23 |
| 30 Jun 17 | 6 | -61 | 11 | 23 |
| 31 Mar 17 | 6 | -60 | 11 | 24 |
| 31 Dec 16 | 7 | -60 | 11 | 25 |
| 30 Sep 16 | 8 | -47 | 14 | 24 |
| 30 Jun 16 | 9 | -34 | 17 | 23 |
| 31 Mar 16 | 10 | -36 | 21 | 22 |
| 31 Dec 15 | 11 | -38 | 26 | 21 |
Quality Earnings: TBGN.F is currently unprofitable.
Growing Profit Margin: TBGN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TBGN.F is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare TBGN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TBGN.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
Return on Equity
High ROE: TBGN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.